paliperidone palmitate

FDA Drug Profile — INVEGA TRINZA, Erzofri extended-release, INVEGA HAFYERA, INVEGA SUSTENNA

paliperidone palmitate is listed in the FDA National Drug Code directory with 17 NDC codes, marketed under brand names including INVEGA TRINZA, Erzofri extended-release, INVEGA HAFYERA. Available dosage forms: injection, suspension, extended release, injection.

Drug details

Generic Name
paliperidone palmitate
Brand Names
INVEGA TRINZA, Erzofri extended-release, INVEGA HAFYERA, INVEGA SUSTENNA
Application Number
NDA207946
Sponsor
Janssen Pharmaceuticals, Inc
NDC Codes
17
Dosage Forms
INJECTION, SUSPENSION, EXTENDED RELEASE, INJECTION
Routes
INTRAMUSCULAR
Active Ingredients
PALIPERIDONE PALMITATE

Indications and Usage

1 INDICATIONS AND USAGE ERZOFRI is indicated for the treatment of: Schizophrenia in adults . Schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants . ERZOFRI is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 ) Treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.